AstraZeneca(US:AZN) 第一财经·2026-01-29 13:43Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to expand its pharmaceutical production and R&D capabilities, leveraging China's scientific and manufacturing strengths to deliver innovative therapies to patients globally [3][4]. Investment Plans - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, enhancing AstraZeneca's capabilities in cell therapy and radiolabeled drugs [4]. - This commitment follows a previous investment of up to 2.5 billion USD announced in March 2022 for establishing a strategic R&D center in Beijing, marking AstraZeneca's second such center in China [3]. R&D and Product Pipeline - Since 2023, AstraZeneca has invested over 1.8 billion USD to strengthen its manufacturing in China and plans to launch 20 global innovative drugs by the end of 2030 [4]. - As of January 2024, AstraZeneca's R&D pipeline in China includes over 200 projects, with 10-15 new projects added annually [4].